NO20065227L - Menoklonale antistoff mot hepatocytt vekstfaktor - Google Patents

Menoklonale antistoff mot hepatocytt vekstfaktor

Info

Publication number
NO20065227L
NO20065227L NO20065227A NO20065227A NO20065227L NO 20065227 L NO20065227 L NO 20065227L NO 20065227 A NO20065227 A NO 20065227A NO 20065227 A NO20065227 A NO 20065227A NO 20065227 L NO20065227 L NO 20065227L
Authority
NO
Norway
Prior art keywords
growth factor
hepatocyte growth
antibody
menoclonal
pharmaceutical composition
Prior art date
Application number
NO20065227A
Other languages
English (en)
Inventor
Jin Kyong Kim
Yi-Chi Su
Lihong Wang
Original Assignee
Galaxy Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35320045&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20065227(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc
Publication of NO20065227L publication Critical patent/NO20065227L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Sammendrag Oppfinnelsen er rettet på et nøytraliserende monoklonalt antistoff til hepatocyttvekstfaktor, en farmasøytisk blanding omfattende det samme, og fremgangsmåte for behandling omfattende at en pasient tilføres en slik farmasøytisk blanding, som for eksempel for å inhibere glioblasom.
NO20065227A 2004-04-15 2006-11-14 Menoklonale antistoff mot hepatocytt vekstfaktor NO20065227L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/825,060 US20040208876A1 (en) 2003-04-18 2004-04-15 Monoclonal antibodies to hepatocyte growth factor
PCT/US2004/026565 WO2005107800A1 (en) 2004-04-15 2004-08-13 Monoclonal antibodies to hepatocyte growth factor

Publications (1)

Publication Number Publication Date
NO20065227L true NO20065227L (no) 2007-01-10

Family

ID=35320045

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065227A NO20065227L (no) 2004-04-15 2006-11-14 Menoklonale antistoff mot hepatocytt vekstfaktor

Country Status (26)

Country Link
US (5) US20040208876A1 (no)
EP (2) EP2204191A1 (no)
JP (2) JP4594381B2 (no)
KR (1) KR101072736B1 (no)
CN (1) CN1964738A (no)
AT (1) ATE473760T1 (no)
AU (1) AU2004319276C1 (no)
BR (1) BRPI0418745A (no)
CA (1) CA2563080C (no)
CR (1) CR8698A (no)
CY (1) CY1110783T1 (no)
DE (1) DE602004028168D1 (no)
DK (1) DK1734995T3 (no)
ES (1) ES2346886T3 (no)
HK (1) HK1094167A1 (no)
HR (1) HRP20100521T1 (no)
IL (1) IL178474A (no)
MX (1) MXPA06011822A (no)
NO (1) NO20065227L (no)
NZ (1) NZ550324A (no)
PL (1) PL1734995T3 (no)
PT (1) PT1734995E (no)
RU (1) RU2361879C2 (no)
SI (1) SI1734995T1 (no)
WO (1) WO2005107800A1 (no)
ZA (1) ZA200609407B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
PT1773885E (pt) * 2004-08-05 2010-07-21 Genentech Inc Antagonistas anti-cmet humanizados
CA2607699A1 (en) * 2005-06-02 2006-12-07 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
RU2446826C2 (ru) 2005-10-14 2012-04-10 Фукуока Юниверсити Агенты для подавления повреждения трансплантированных островков после трансплантации островков
AR058135A1 (es) 2005-10-21 2008-01-23 Chugai Pharmaceutical Co Ltd Agentes para el tratamiento de cardiopatias
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AR057941A1 (es) * 2005-11-25 2007-12-26 Univ Keio Agentes terapeuticos para el cancer de prostata
JP5033643B2 (ja) 2006-01-27 2012-09-26 学校法人慶應義塾 脈絡膜血管新生を伴う疾患の治療剤
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
CA2648644C (en) 2006-04-07 2016-01-05 Osaka University Muscle regeneration promoter
KR101196184B1 (ko) * 2006-06-02 2012-11-01 아베오 파마슈티컬즈, 인크. 간세포 성장 인자 (ｈｇｆ) 결합 단백질
AU2007254942B2 (en) 2006-06-02 2011-10-27 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (HGF) binding proteins
RU2450829C2 (ru) 2007-01-23 2012-05-20 Синсу Юниверсити Ингибитор хронического отторжения
EP2170268A2 (en) * 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
JP5699075B2 (ja) * 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
CN102256623A (zh) 2008-06-05 2011-11-23 独立行政法人国立癌症研究中心 神经浸润抑制剂
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
US20120052064A1 (en) * 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
CN101555912B (zh) * 2009-04-29 2012-10-03 深圳市特辰科技股份有限公司 一种转轮式自锁安全制动装置及其工作方法
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
PL2578231T3 (pl) 2010-05-28 2023-01-16 Chugai Seiyaku Kabushiki Kaisha Środek wzmacniający przeciwnowotworową odpowiedź limfocytów t
US20130315895A1 (en) 2010-07-01 2013-11-28 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
KR20140045440A (ko) 2011-06-30 2014-04-16 제넨테크, 인크. 항-c-met 항체 제제
CZ2011514A3 (cs) * 2011-08-19 2013-01-23 Invos, Spol. S R. O. Biokontejner pro sber bioodpadu a komunálního odpadu
CN103974720A (zh) 2011-09-09 2014-08-06 安姆根有限公司 C-met蛋白质用于预测抗肝细胞生长因子(“hgf”)抗体在食管癌和胃癌患者中的功效的用途
JP2014530201A (ja) 2011-09-20 2014-11-17 イーライ リリー アンド カンパニー 抗ｃ−Ｍｅｔ抗体
EP2873422A4 (en) 2012-07-10 2015-12-30 Takeda Pharmaceutical PHARMACEUTICAL PREPARATION FOR INJECTION
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
CA2904743A1 (en) * 2013-03-14 2014-09-25 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
WO2015031578A1 (en) * 2013-08-28 2015-03-05 Abbvie Inc. Hgf assay
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US722041A (en) * 1902-11-24 1903-03-03 Mail Belting Company Conveyer-belt.
JP2564486B2 (ja) 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
GB9003621D0 (en) 1990-02-16 1990-04-11 Imp Cancer Res Tech Protein factor
GB9009548D0 (en) * 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US6498144B1 (en) 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE465257T1 (de) * 1996-07-03 2010-05-15 Genentech Inc Agonisten für den rezeptor des hepatozyten- wachstumsfaktors und deren anwendungen
AU5588099A (en) 1998-08-28 2000-03-21 Dendreon Corporation Selective apoptosis of neoplastic cells by an hla-dr specific monoclonal antibody
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
EP1423432A4 (en) 2001-07-26 2006-01-11 Lilly Co Eli ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
JP2005527488A (ja) 2001-12-27 2005-09-15 バン アンデル リサーチ インスティチュート Ｍｅｔを発現し、肝細胞増殖因子と結合する腫瘍のモノクローナル抗体画像化および治療
WO2004019991A2 (en) * 2002-08-30 2004-03-11 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
DK1636593T5 (da) 2003-06-06 2009-07-27 Genentech Inc Modulering af vekselvirkningen mellem HGF-beta-kæde og c-met
DE602004024536D1 (de) 2003-07-07 2010-01-21 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
CA2607699A1 (en) 2005-06-02 2006-12-07 Galaxy Biotech, Llc Methods of treating brain tumors with antibodies
AR059922A1 (es) * 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
MXPA06011822A (es) 2007-03-23
US7687063B2 (en) 2010-03-30
CA2563080A1 (en) 2005-11-17
KR20070012711A (ko) 2007-01-26
NZ550324A (en) 2009-12-24
WO2005107800A1 (en) 2005-11-17
DK1734995T3 (da) 2010-10-25
US20040208876A1 (en) 2004-10-21
IL178474A (en) 2011-04-28
IL178474A0 (en) 2007-02-11
SI1734995T1 (sl) 2010-09-30
BRPI0418745A (pt) 2007-12-11
RU2361879C2 (ru) 2009-07-20
EP2204191A1 (en) 2010-07-07
JP2011012067A (ja) 2011-01-20
EP1734995A1 (en) 2006-12-27
CN1964738A (zh) 2007-05-16
ATE473760T1 (de) 2010-07-15
US20090104192A1 (en) 2009-04-23
EP1734995A4 (en) 2007-04-25
PT1734995E (pt) 2010-08-18
AU2004319276A1 (en) 2005-11-17
RU2006140257A (ru) 2008-05-20
JP2007532643A (ja) 2007-11-15
ES2346886T3 (es) 2010-10-21
HK1094167A1 (en) 2007-03-23
ZA200609407B (en) 2008-07-30
US20070160613A1 (en) 2007-07-12
HRP20100521T1 (hr) 2010-10-31
AU2004319276C1 (en) 2011-03-03
JP4594381B2 (ja) 2010-12-08
KR101072736B1 (ko) 2011-10-11
US7494650B2 (en) 2009-02-24
DE602004028168D1 (de) 2010-08-26
AU2004319276B2 (en) 2010-08-26
US20120064066A1 (en) 2012-03-15
CY1110783T1 (el) 2015-06-10
CA2563080C (en) 2015-01-27
PL1734995T3 (pl) 2010-12-31
EP1734995B1 (en) 2010-07-14
CR8698A (es) 2007-12-17
US20080019966A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
NO20065227L (no) Menoklonale antistoff mot hepatocytt vekstfaktor
MY145042A (en) Humanized monoclonal antibodies to hepatocyte growth factor
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
ATE536188T1 (de) Fcgammariib-spezifische antikörper und verfahren zur verwendung davon
CY1112277T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ΑΝΤΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
EA200700202A1 (ru) Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CY1111622T1 (el) Ανθρωποποιημενοι ανταγωνιστες anti-cmet
DE602004027936D1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
EA201000245A1 (ru) Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf
EA200802213A1 (ru) Способы лечения заболеваний крови
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
DK1713830T3 (da) Anti-epcam-immunglobuliner
DK2109623T3 (da) Cancerbehandling med anti-IL-1-antistoffer
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
EA200702336A1 (ru) ПРИМЕНЕНИЕ 24-норУДХК
DK1869185T3 (da) Konjugat med P21-protein til kræftbehandling
EA200900269A1 (ru) Лекарственные комбинации для лечения заболеваний дыхательных путей
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
DE602004020337D1 (de) Anticholinergika enthaltende Arzneimittel zur Behandlung von Krankheiten der ableitenden Harnwege
ATE503527T1 (de) Selen-haltige medikamente gegen endotheliale gefässerkrankungen
UA2986U (uk) Спосіб лікування розсіяного склерозу

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application